Briacell Therap (NASDAQ:BCTX) Stock Crosses Above Two Hundred Day Moving Average – Here’s What Happened

Briacell Therap (NASDAQ:BCTX) crossed above its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $3.79 and traded as high as $4.08. Briacell Therap shares last traded at $3.95, with a volume of 158,152 shares.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Briacell Therap in a research report on Thursday, October 15th. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

Briacell Therap Stock Up 20.8%

The firm has a 50 day moving average of $3.72 and a 200-day moving average of $3.79. The firm has a market capitalization of $34.48 million, a P/E ratio of -0.43 and a beta of 1.26.

Briacell Therap (NASDAQ:BCTX) last posted its quarterly earnings data on Wednesday, October 28th. The company reported ($1.50) earnings per share for the quarter.

About Briacell Therap

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. Its research is centered on treatments designed to stimulate a patient’s immune system to recognize and attack tumor cells, with an emphasis on advanced breast cancer and other solid tumors.

The company’s lead technology includes Bria-IMT, an off-the-shelf, whole-cell immunotherapy derived from a breast cancer cell line. BriaCell has also been developing Bria-OTS, a personalized immunotherapy approach intended to match treatment with a patient’s human leukocyte antigen profile.